



# Preventing leukemia deaths.

Children with a rare form of leukemia can suffer devastating blood clotting abnormalities that can cause early death before their cancer treatment has a chance to be effective. With the support of the CRCM, oncology researchers are conducting a study investigating new biomarkers of coagulation status in conjunction with a world-wide Children's Oncology Group (COG) therapeutic clinical trial.

CHM's Hematology-Oncology group is conducting this important research in conjunction with a world-wide therapeutic clinical trial. Children will have their blood clotting status assessed using specialized new techniques in an effort to improve clinicians' ability to identify adverse clotting events.

- CHM has an international reputation for expertise in pediatric blood clotting disorders
- CHM's special coagulation laboratory is the designated central coordinating laboratory for all North American trial centers

---

Help prevent leukemia deaths and advance possibilities by visiting [CHMFoundation.org/CRCM](http://CHMFoundation.org/CRCM) or calling 313.745.0318.